TABLE 2.

Association of the messenger RNA (mRNA) signature with clinical characteristics in cutaneous melanoma (CM) patients.

Variables	Training group		p	Test group		p	TCGA group		p
	Low risk*	High risk*		Low risk*	High risk*		Low risk*	High risk*
Age (years)			0.89			0.27			0.57
≤ 58	48	46		38	47		86	93
>58	48	50		58	50		106	100
Gender			0.38			1.00			0.50
Female	43	36		33	33		76	69
Male	53	60		63	64		116	124
Radiotherapy			<0.001			0.13			<0.001
Unknown	25	50		29	41		54	91
No	63	42		57	51		120	93
Yes	8	4		10	5		18	9
Pathological M			0.33			0.52			0.21
M0	84	89		82	86		166	175
M1	6	5		5	6		11	11
Pathological N			0.56			0.31			0.19
N0	48	44		42	37		90	81
N1	14	19		19	16		33	35
N2	11	9		12	12		23	21
N3	11	16		10	18		21	34
Pathological T			0.17			0.31			0.27
T0	5	1		6	7		11	8
T1	12	9		8	1		20	10
T2	16	17		12	14		28	31
T3	16	25		17	17		33	42
T4	30	37		35	41		65	78
Tumor stage			0.31			0.87			0.38
Stage 0	0	1		1	0		1	1
Stage I	20	14		11	9		31	23
I/II Nos	2	0		1	0		3	0
Stage II	29	31		29	31		58	62
Stage III	32	42		41	44		73	86
Stage IV	6	5		5	6		11	11
Race demographic			0.22			0.03			0.51
Asian	3	3		2	4		5	7
White	93	90		88	93		181	183

*Low risk ≤ median of risk score, high risk > median of risk score.